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A consistent finding in Swedish (Gilljam & Galanti; Ramström & 
Foulds, 2006; Stenbeck, Hagquist, & Rosén, 2009) and Norwegian 
(Lund, 2009b; Scheffels & Lund, 2009) observational studies is 
that the quit rate for smoking is higher for snus users than for 
smokers who have no experience of use of snus. To our knowl-
edge, other than a few small pilot studies (Mendoza-Baumgart 
et al., 2007; Tilashalski, Rodu, & Cole, 1998), no randomized 
controlled trials (RCT) or experimental studies have been car-
ried out to compare the effect of snus and medicinal nicotine 
products on quitting smoking. In the absence of such studies, 
self-reported data have been used to shed light on the effect of 
the  different  methods  for  quitting  smoking  (Ramström  & 
Foulds), although the degree of evidence is lower.
We  examined  the  self-reported  outcome  of  smokers’  
attempts to quit smoking using the following methods of quitting: 
snus,  nicotine  patches,  nicotine  chewing  gum,  bupropion   
(Zyban), and varenicline (Champix).
Methods
An invitation to participate in the survey was sent by E-mail to 
14,744 men aged 20–50 years in 2007, who had been randomly 
selected from a web panel of 62,000 Norwegians administrated by 
the international research agency Synovate. People were recruited 
to this web panel when they had participated in previous nation-
ally representative population surveys, carried out by telephone, 
post, or personal interview and had agreed to receive future invi-
tations to participate in surveys by E-mail. Self-recruitment to the 
panel was not possible. Of those invited to participate, 7,170 men 
(48.6%) responded. No significant differences at the 5% level 
were detected in the distributions of the national population and 
the respondents when compared by age and region.
The final sample consisted of 1,775 former daily or occa-
sional smokers and 1,808 current daily or occasional smokers, a 
total of 3,583 people. Former smokers and smokers who had 
tried to quit were asked “Did you use some of these methods 
when you last tried to quit smoking (multiple answers possi-
ble)?” Response categories were nicotine gum, nicotine patch, 
snus,  inhaler,  Zyban,  Champix,  called  the  quitline,  attended   
a course or consulted health personnel, and read brochures/ 
self-help  material  (Table  1).  The  association  between  using   
Abstract
Introduction: Given there are few experimental studies com-
paring the effects of snus and medicinal products for quitting 
smoking, self-reports from smokers who have used different 
methods for quitting smoking can be informative.
Methods: Fourteen thousand seven hundred and forty-four 
Norwegian men aged between 20 and 50 years were selected at 
random from a national representative web panel and sent a 
questionnaire by E-mail. Of the 7,170 (48.6%) who responded, 
there were 1,775 former and 1,808 current smokers. They were 
asked about the method they used and the outcome of their last 
attempt to quit smoking.
Results: In a regression model in which education, number of 
previous attempts to quit smoking, perception of risk, and age 
were controlled for, the odds ratio (OR) for reporting total absti-
nence at the time of the survey was significantly higher for those 
who had used varenicline (OR = 4.95, p < .006) and snus (OR = 
2.68, p < .001) compared with those who had used nicotine 
chewing gum (reference OR = 1). For smokers who reported 
that they had tried to quit with the help of snus, 62.4% reported 
that they still used snus at the time of the survey either daily 
(43.8%) or occasionally (18.6%). The proportion who still used 
medicinal nicotine products at the time of the survey was 9.5%.
Discussion: Compared with medicinal nicotine products, snus 
and varenicline increased the probability of quitting smoking 
completely, but snus seemed to maintain nicotine dependence.
Introduction
In general, the Nordic health authorities do not recommend use 
of snus as a method for quitting smoking (Holm, Fisker, Larsen, 
Puska, & Halldórsson, 2009), although in Norway, they have 
recently agreed that health care personnel can recommend snus 
in individual cases of inveterate smokers (Norwegian Directorate 
of Health, 2009). However, studies have shown that snus is the 
preferred method for quitting among male smokers in Sweden 
and Norway, and this method is also used by an increasing 
number of women (Gilljam & Galanti, 2003; Lund, 2009a).  
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different methods was measured by Pearson’s coefficients that 
can range in value from −1 (a perfect negative relationship)   
to +1 (a perfect positive relationship). Use of one method pre-
dicts the use of another method if correlation between the two 
was positive and significantly different from 0 (no relationship). 
If use of one method reduced the probability to take up an ad-
ditional method, the correlation had a negative sign (Table 2). 
Correlation coefficients significant at the .05 level were identi-
fied with a single asterisk, and those significant at the .01 level 
were identified with two asterisks.
The respondents were also asked “What was the result of 
your latest attempt to quit smoking?” The response categories 
were quit smoking completely, greatly reduced their cigarette 
consumption, reduced their cigarette consumption somewhat, 
and smoked about the same as before. The odds ratios (ORs) 
for reporting “quit smoking completely” (table 3), and then in 
another model “greatly reduced cigarette consumption” (table 4), 
were calculated using logistic regression controlling for method 
for quitting, length of highest completed education, number   
of previous attempts to quit, risk perception, and age. Only 
people who reported using only one of nicotine chewing gum, 
nicotine patches, snus, bupropion, or varenicline were included 
in the regression analysis. However, these respondents could 
have used other methods for quitting smoking, such as self-
help materials, a telephone helpline for smoking, or consulta-
tion  with  health  care  personnel.  In  the  model  for  Table  4, 
respondents who had quit smoking completely were excluded 
from the analysis.
Perception of risk was measured using the question “On a 
scale from 1 to 7, where 1 is ‘not dangerous’ and 7 is ‘very dan-
gerous’, how dangerous to health do you believe use of cigarettes 
is?” For use in the regression analysis, the scores were grouped 
into three values by splitting the sample in “low” (range 1–5), 
“medium” (6), and “high score” (7). Scores for age and number 
of attempts to quit were grouped into three values by splitting 
the sample at the values closest to the 33rd and 66th percentile.
Results
Snus was the most common method for quitting smoking, fol-
lowed by nicotine chewing gum, self-help materials, and nico-
tine patches (Table 1). The proportion of current smokers (and 
thus unsuccessful quitters) was greater than the proportion of 
former smokers (and thus successful quitters) for all methods 
for quitting smoking. However, the ratio of successful to unsuc-
cessful quitters was higher for snus than for the other methods 
for quitting smoking.
Just under half (n = 1,727, 48.2%) of current or former 
smokers reported that they had used at least one of the nine 
specified methods to try to quit smoking on their last attempt. 
Table 1. Percentage using different methods for quitting smoking on last quit attempt 
among ever smokers, former smokers, and current smokers (multiple choice of methods 
possible), and ratio of former/current smokers for each quit-smoking method
Ever smokers  
(N = 3583)
Former smokers  
(N = 1775)
Current smokers  
(N = 1808) Chi-square p value
Ratio former/current  
smokers
Nicotine chewing gum 18.0 (n = 646) 9.4 (n = 166) 26.5 (n = 480) 179.2 <.001 0.35
Nicotine patch 10.3 (n = 368) 4.7 (n = 85) 15.7 (n = 284) 117.2 <.001 0.30
Snus 31.6 (n = 1134) 26.1 (n = 463) 37.1 (n = 671) 50.4 <.001 0.70
Inhaler 1.8 (n = 65) 0.9 (n = 16) 2.7 (n = 49) 16.5 <.001 0.33
Zyban 4.7 (n = 167) 2.6 (n = 47) 6.6 (n = 120) 32.1 <.001 0.39
Champix 1.1 (n = 38) 0.7 (n = 12) 1.4 (n = 26) 5.0 .026 0.50
Telephone helpline for smoking 1.3 (n = 48) 0.5 (n = 9) 2.2 (n = 39) 18.5 <.001 0.23
Help from health care personnel 3.6 (n = 128) 2.1 (n = 37) 5.0 (n = 91) 22.6 <.001 0.42
Self-help material 12.1 (n = 434) 7.5 (n = 133) 16.7 (n = 301) 70.6 <.001 0.45
Table 2. Relationship between methods of quitting. Bivariate correlations (Pearson) with 
asterisks identifying significant associations
Snus Nicotine chewing gum Nicotine patch Inhaler Zyban Champix
Snus
Nicotine chewing gum −0.439**
Nicotine patch −0.341** 0.253**
Inhaler −0.100** 0.124* 0.075
Zyban −0.271** 0.051* 0.107* 0.079**
Champix −0.149** −0.018 0.066** 0.074** 0.125**
Telephone helpline for smoking −0.060* 0.110** 0.136** 0.101** 0.148** 0.146**
Help from health care personnel −0.165** 0.147** 0.172** 0.096** 0.131** 0.083**
Self-help material −0.162** 0.253** 0.154** 0.113** 0.145** 0.042
Note. **Correlation at .01 (two tailed), *correlation at .05 (two tailed).819
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While  use  of  a  conventional  method,  recommended  by  the   
authorities, consistently increased the probability for also using 
one of the other recommended methods, use of snus was sig-
nificantly negatively correlated with all the other methods of 
quitting smoking (Table 2).
The OR of reporting total abstinence at the time of the survey, 
when controlling for the other factors, was significantly higher 
for use of snus only than for use of one of any of the other methods 
for quitting. Fewer previous attempts to quit, concern about the 
health risks, and increasing age also increased the probability for 
having quit smoking (Table 3). In a model predicting “greatly 
reduced cigarette consumption,” the significant predictors were 
reduced to use of snus as the method for quitting and length of 
education (Table 4).
Of those smokers who reported that they had tried to quit 
by using snus, 62.4% reported that they still used snus at the 
time of the survey, either daily (43.8%) or occasionally (18.6%). 
People who had quit completely or greatly reduced their ciga-
rette consumption with the help of snus were more likely to use 
snus on a daily basis than people whose attempt to quit had   
resulted in less change in cigarette consumption. In compari-
son, only 9.5% who had used nicotine chewing gum or nicotine 
patches at the last attempt to quit were still using these medicinal 
nicotine products at the time of the survey (Table 5).
Discussion
The study has shown that snus is the preferred method for quit-
ting smoking for men in the age group 20–50 years. In addition, 
those using snus were more likely to have quit smoking com-
pletely or considerably reduced their cigarette smoking than   
users of medicinal smoking cessation products. This is the case 
despite the fact that users of medicinal nicotine products had a 
greater tendency to use additional methods for quitting smoking, 
which would normally increase the probability of a positive re-
sult. Use of snus seemed to be a more solitary method and might 
appear convenient for smokers who for some reason do not 
want to make use of the nicotine replacement therapy medicinal 
products. However, the survey indicates that use of snus as a 
method for quitting smoking may result in continued use after 
the attempt to quit. Such prolonged use of snus not only oc-
curred among those who quit smoking or who greatly reduced 
their cigarette consumption but also among those who man-
aged to change their cigarette consumption to a lesser extent.
Limitations
The  study  has  weaknesses  common  to  other  cross-sectional   
surveys using self-reported data. In contrast to an RCT, our study 
design does not ensure comparability of different groups. Thus, 
the  possibility  cannot  be  excluded  that  there  are  differences   
between the groups with regard to variables that can influence 
Table 3. Percentage (bivariate) and  
adjusted odds ratios (AORs) for having quit 
smoking completely at the last attempt for 
men aged 20–50 years. Odds ratio is 
adjusted for method of quitting, length of 
education, number of previous attempts to 
quit, risk perception, and age group
% n/N AOR p value
Method
  Nicotine chewing gum (ref) 36.6 83/227 1.00
  Nicotine patch 38.9 35/90 0.96 .866
  Snus 54.8 454/828 2.66 <.001
  Zyban 47.5 28/59 1.56 .148
  Champix 68.8 11/16 5.05 .006
Education
  Compulsory school (ref) 47.3 139/294 1.00
  Upper secondary school 49.9 722/1447 1.09 .736
  University/college 62.0 1142/1842 1.54 .072
Previous attempts to quit
  1 (ref) 76.3 997/1307 1.00
  2–3 45.0 601/1335 0.40 <.001
  4 or more 43.0 405/941 0.32 <.001
Score for perception of health risk
  Low (ref) 41.2 192/466 1.00
  Medium 47.9 374/780 1.23 .341
  High 61.5 1437/2337 2.38 <.001
Age
  20–35 years 53.1 661/1244 1.00
  36–43 years 54.6 658/1205 1.96 <.001
  44–50 years 60.3 684/1134 2.74 <.001
Table 4. Percentage (bivariate) and  
adjusted odds ratio (AOR) for having greatly   
reduced cigarette consumption at the last 
attempt for men aged 20-50 years. OR is 
adjusted for method of quitting, length of 
education, number of previous attempts to 
quit, risk perception and age group
% n/N AOR p value
Method
  Nicotine chewing gum (ref) 18.1 41/227 1.00
  Nicotine patch 15.6 14/90 0.68 .394
  Snus 25.5 211/828 3.01 <.001
  Zyban 6.8 4/59 0.11 .323
  Champix 18.8 3/16 8.94 .999
Education
  Compulsory school (ref) 9.9 29/294 1.00
  Upper secondary school 16.9 244/1447 3.49 .011
  University/college 16.7 307/1842 4.38 .002
Previous attempts to quit
  1 (ref) 9.9 129/1307 1.00
  2–3 18.4 246/1335 0.68 .261
  4 or more 21.8 205/941 0.46 .032
Score for perception of health risk
  Low (ref) 18.5 86/466 1.00
  Medium 17.7 138/780 1.02 .948
  High 15.2 356/2337 1.52 .221
Age
  20–35 years 20.4 254/1244 1.00
  36–43 years 15.6 188/1205 1.54 .169
  44–50 years 12.2 138/1134 1.69 .151820
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the outcome of an attempt to quit smoking, such as smoking 
intensity, smoking history, degree of nicotine dependence, and 
strength of intention to quit smoking. We have controlled for 
some variables (age, number of previous attempts to quit smok-
ing, perception of risk, and education), which compensate to 
some extent—but not fully—for the absence of randomization. 
However, the current kind of observational studies are superior 
to RCT when it comes to evaluate effectiveness under real life 
conditions for different smoking cessation methods.
Another weakness is that we do not have data about the 
length of time from the attempt to quit smoking to the time of 
the survey. We cannot exclude the possibility that there are   
systematic differences between smokers who use the different 
methods, with regard to length of time between attempts to quit 
smoking or recall of quit attempts, but there is not any obvious 
reason that this would be the case. Respondents with an over-
average interest in smoking cessation might be overrepresented 
in studies like this, but again, we find no reason that this interest 
should be systematically imbalanced between users of the differ-
ent methods. Finally, the outcomes studied here are self-reports, 
and these are not validated with biochemical markers. Thus, 
there  is  a  need  to  carry  out  experimental  studies  that  can   
provide more robust evidence.
Use of snus for smoking cessation 
rather than medicinal products
In accordance with other research (Lund, 2009a,  2009b; Scheffels & 
Lund, 2009), our study shows that medicinal nicotine products 
are not the most popular method chosen by Norwegian smok-
ers to quit smoking. This is the case even though the pharma-
ceutical companies have, for nearly 25 years, widely advertised 
these  products  as  effective  stop-smoking  aids,  that  they  are 
widely accessible over-the-counter products, and given recom-
mendations by the health authorities. The low utilization is re-
lated to, among other things, the fact that they are deliberately 
made unattractive in order to avoid misuse and that they give a 
much lower dose of nicotine than cigarettes. The first genera-
tion of nicotine chewing gum was made with an unpleasant 
taste in order for it to be authorized for sale but is now on the 
market with flavors of mint, fruit, or liquorice.
With regard to snus, its effect on quitting smoking is not 
advertised and is unknown to the public (Scientific Committee 
on Emerging and Newly Identified Health Risks [SCENIHR], 
2008), the health authorities advise against its use, the percep-
tion of health risks are exaggerated in the population (Øverland, 
Hetland, & Aarø, 2008), and the price is only a bit lower than 
the price of cigarettes. Some of the reasons why snus still has 
greater potential for use than medicinal nicotine products are 
that  the  nicotine  dose  is  almost  the  same  as  for  cigarettes   
(Hatsukami, Ebbert, Feuer, Stepanov, & Hecht, 2007) and that the 
choice of brand, aesthetic rituals of use, and visibility can repre-
sent social positioning and self presentation (Nordby & Wood 
2008). Use of snus can thus—in contrast to nicotine chewing 
gum and nicotine patches—have functions that are identical to 
those offered by cigarettes. In addition, snus, similar to ciga-
rettes, tastes of tobacco and thus has a sensory effect that me-
dicinal nicotine products perhaps lack. This suggests that snus is 
the only nicotine product on the Norwegian market that can 
compete in popularity with cigarettes (Lund, 2009a). The like-
ability of snus implies that the impact on smoking cessation at 
the population level (effectiveness) will be higher than medicinal 
nicotine products. This would be the case even if, hypothetically, 
future RCTs should moderate our results in finding that use of 
snus results in no increase in rates of abstinence (efficacy).
The higher rates of snus use among those using snus on 
their last quit attempt may be an indication that use of snus 
when quitting smoking contributes to maintaining dependence 
on nicotine and that the method can result in dual use for those 
whose attempt to quit has been unsuccessful. Against this back-
ground,  advice  against  using  snus  as  a  method  for  quitting 
smoking as a general strategy seems to be sensible. However, the 
method could be particularly relevant for intransigent smokers 
who  are  seriously  addicted  to  nicotine  and  who  have  been   
unsuccessful in quitting using conventional methods. For these 
people,  as  for  all  other  smokers,  nicotine  uptake  from  snus   
instead of from cigarettes has the potential for reducing harm by 
at least 90% (Levy et al., 2004). It should also be emphasized 
that  a  substantial  fraction  (37.6%)  of  those  using  snus  as   
a method for quitting in fact ended up tobacco free, as also   
observed in Sweden (Ramström & Foulds, 2006).
A possible negative consequence of allowing use of snus as a 
method for quitting among inveterate smokers is that the method 
would  not  only  be  used  by  these  highly  nicotine-dependent 
smokers. A partial approval of snus as a potential quit smoking 
method might result in many smokers, who otherwise would 
have  been  able  to  quit  using  tobacco  completely,  would  be   
recruited  into  prolonged  nicotine  dependence  from  snus.   
In this connection, a relevant challenge for further research is to 
find out whether transition from cigarettes to snus will increase 
or decrease the risk of future relapse to smoking as compared 
with nonswitchers.
Table 5. Proportion of men 20–50 years old who used snus or medicinal nicotine products 
to quit smoking who were using these products at the time of the survey
Method used at last quit attempt Snus Nicotine chewing gum/nicotine patch
Current use Daily Occasionally Never Total (N) Daily Occasionally Never Total (N)
Outcome of last quit attempt
  Quitted smoking completely 54.0 11.2 34.8 100 (572) 5.1 4.2 90.7 100 (118)
  Great reduction in cigarette consumption 59.8 14.7 25.6 100 (266) 10.9 9.1 80.0 100 (55)
  Some reduction in cigarette consumption 15.5 37.9 46.6 100 (103) 0 4.7 95.3 100 (43)
  Smokes as previously 8.3 34.8 56.9 100 (204) 0 5.9 94.1 100 (101)
  All 43.8 18.6 37.6 100 (1145) 3.8 5.7 90.5 100 (317)821
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Why is snus more effective than 
medicinal nicotine products?
Of 100 people who try to quit smoking, about 95 will relapse 
within 6 months without using medicinal nicotine products. 
At best, only five more people will quit smoking completely by 
using medicinal nicotine products (Hughes, Shiffman, Callas, & 
Zhang, 2003). It has been calculated that availability of nonpre-
scription medicinal nicotine products has had no measurable ef-
fect on the quit rate for smoking in the United States (Cummings 
& Hyland, 2005). This is primarily because so few smokers use 
these products but also because the effect of medicinal nicotine 
products is quite low when measured after 12 months (Stead, 
Perera, Bullen, Mant, & Lancaster, 2008) and is even lower later 
(Etter & Stapleton, 2006). So snus does not need to have a very 
great effect on the quit rate in order to produce better results 
than medicinal nicotine products. Studies have shown that 
varenicline (Champix) has a much better effect than medicinal 
nicotine products (Aubin et al., 2008)—which our study has 
also shown—but this product is only available on prescription, 
is relatively new and not widely used, and will thus not have a 
great effect on the quit rate at the population level unless there 
is a great increase in demand.
We must assume that the most important reason why snus is 
reported to be more effective for quitting smoking than medicinal 
nicotine products is that it provides a high enough dose of nico-
tine so that it feels satisfying for smokers (Hatsukami et al., 2007).
Since snus contains carcinogenic substances and increases 
the risk of cancer of the esophagus and the pancreas—though 
lower  than  for  smoking  (SCENIHR,  2008)—there  would  be 
ethical objections to carrying out an RCT. An alternative design 
would be to divide people who call the quitline according to 
method for quitting smoking, to measure other variables that 
have significance for quitting smoking at the baseline, and then 
to follow up these people prospectively, as has been done in 
Sweden (Helgason et al., 2004).
The study indicates that use of varenicline and snus increases 
the  probability  of  a  positive  outcome  of  an  attempt  to  quit 
smoking compared with medicinal nicotine products. This is 
the case despite the fact that users of medicinal nicotine products 
have a greater tendency than snus users to use other additional 
methods that have a positive effect on quitting smoking. Further 
studies should be carried out with a design that can provide better 
evidence. Prolonged use of snus was also widespread among 
smokers who made unsuccessful attempts to quit smoking. As a 
method for quitting smoking, snus should only be considered 
for seriously nicotine-dependent smokers who have previously 
been unsuccessful with other methods.
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